Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

T-helper/T-regulator lymphocyte ratio as a new immunobiological index to quantify the anticancer immune status in cancer patients.

Brivio F, Fumagalli L, Parolini D, Messina G, Rovelli F, Rescaldani R, Vigore L, Vezzo R, Vaghi M, Di Bella S, Lissoni P.

In Vivo. 2008 Sep-Oct;22(5):647-50.

2.

Lack of evidence for Borrelia burgdorferi seropositivity in Alzheimer disease.

Galbussera A, Tremolizzo L, Isella V, Gelosa G, Vezzo R, Vigorè L, Brenna M, Ferrarese C, Appollonio I.

Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):308. doi: 10.1097/WAD.0b013e31816ba95d. No abstract available.

PMID:
18769174
3.

Evaluation of the Abbott AxSYM cytomegalovirus (CMV) immunoglobulin M (IgM) assay in conjunction with other CMV IgM tests and a CMV IgG avidity assay.

Lazzarotto T, Galli C, Pulvirenti R, Rescaldani R, Vezzo R, La Gioia A, Martinelli C, La Rocca S, Agresti G, Grillner L, Nordin M, van Ranst M, Combs B, Maine GT, Landini MP.

Clin Diagn Lab Immunol. 2001 Jan;8(1):196-8.

4.

Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2.

Lissoni P, Barni S, Andres M, Scardino E, Vigoré L, Vezzo R, Rescaldani R, Tancini G.

Tumori. 1994 Aug 31;80(4):283-5.

PMID:
7974799
5.

Immunotherapy with low-dose subcutaneous interleukin-2 plus beta-interferon as a second-line therapy for metastatic colorectal carcinoma.

Barni S, Lissoni P, Ardizzola A, Vigoré L, Vezzo R, Rescaldani R, Tancini G.

Tumori. 1993 Oct 31;79(5):343-6.

PMID:
8116079

Supplemental Content

Support Center